Celecoxib enhances apoptosis of the liver cancer cells via regulating ERK/JNK/P38 pathway

Zhe Jia*, Haitao Zhang*, Chao Ma, Ning Li, Menglong Wang
Department of General Surgery, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
*Zhe Jia and Haitao Zhang contributed equally to this work.

Summary

**Purpose:** We aimed to investigate the effect of celecoxib on rats with liver cancer through the extracellular signal-regulated kinase (ERK)/c-Jun N-terminal kinase (JNK)/p38 pathway.

**Methods:** Sprague-Dawley rats (n=36) were divided into 3 groups (n=12 per group) randomly. In model group, the liver cancer model was established, and normal saline was intraperitoneally injected. In celecoxib group, the liver cancer model was also established, and celecoxib was intraperitoneally injected. After intervention for 30 d, the samples were taken. The body weight of rats was measured before modeling and before sampling. The morphology of liver tissues was observed via hematoxylin-eosin (HE) staining, the expressions of related proteins and messenger ribonucleic acids (mRNAs) were determined via Western blotting and quantitative polymerase chain reaction (qPCR), respectively, and the protein expressions of cysteinyl aspartate specific proteinase 3 (Caspase3) and Cyclin D1 in liver tissues were detected.

**Results:** Before modeling, there was no difference in the body weight of rats among groups. Before sampling, the body weight of rats was smaller in model group and celecoxib group than that in normal group, while it was larger in celecoxib group than that in model group. It was observed using HE staining that the morphology of liver tissues was normal in normal group, it was disordered, with a large number of tumor cells in model group, and it was a little disordered but improved in celecoxib group compared with that in model group. Furthermore, the protein expression of phosphorylated ERK (p-ERK) significantly rose, while the relative protein expressions of p-JNK and p-p38 significantly declined in the other two groups compared with those in normal group. Compared with those in model group, the relative protein expression of p-ERK obviously declined, while the relative protein expressions of p-JNK and p-p38 obviously rose in celecoxib group. It was found via qPCR that the relative mRNA expression of Caspase3 was markedly lower, while that of Cyclin D1 was markedly higher in the other two groups than those in normal group. The relative mRNA expression of Caspase3 was markedly higher, while that of Cyclin D1 was markedly lower in celecoxib group than those in model group. In addition, according to the results of ELISA, the relative protein expression of Caspase3 greatly declined, while that of Cyclin D1 greatly rose in the other two groups compared with those in normal group. The relative protein expression of Caspase3 greatly rose, while that of Cyclin D1 greatly declined in celecoxib group compared with those in model group. Finally, according to the results of TUNEL assay showed that the apoptosis rate was remarkably decreased in the other two groups compared with that in normal group, while it was remarkably increased in celecoxib group compared with that in model group.

**Conclusion:** Celecoxib affects the apoptosis of liver cancer cells through regulating the ERK/JNK/p38 signaling pathway, thereby exerting an anti-tumor effect.

**Key words:** liver cancer, celecoxib, apoptosis, ERK/JNK/p38 signaling pathway.

Introduction

Liver cancer is a clinically common malignant tumor of the digestive system, whose morbidity and mortality rates are high, making it one of the major tumors endangering human life and health [1,2]. According to the literature, the morbidity rate of liver cancer is relatively high in China. In par-
Celecoxib in rats with liver cancer

Celecoxib is a commonly used antipyretic and analgesic drug, and it has a good selective inhibitory effect on cyclooxygenase-2. According to recent studies [8, 9], celecoxib exerts an excellent anti-tumor effect, but its related mechanism remains unclear. Therefore, the purpose of this study was to study the effect of celecoxib in rats with liver cancer through the ERK/JNK/p38 pathway.

Methods

Laboratory animals and grouping

A total of 36 Sprague-Dawley rats (200±20 g, 6-8 weeks) were divided into normal group (n=12), model group (n=12) and celecoxib group (n=12) using a random number table. They were adaptively fed with adequate food and water for 1 week. The Animal Ethics Committee of Capital Medical University Animal Center approved the present study.

Laboratory reagents and instruments

Celecoxib was provided by Pfizer Pharmaceuticals (Dalian, China), and primary antibodies against phosphorylated ERK (p-ERK), p-JNK and p-p38 antibodies and goat anti-rabbit secondary antibody were provided by Abcam (Cambridge, MA, USA). Hematoxylin-eosin (HE) staining kits, enzyme-linked immunosorbent assay (ELISA) kits and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay kits were purchased from Boster (Wuhan, China), and quantitative polymerase chain reaction (qPCR) kits were purchased from Vazyme (Nanjing, China). A light microscope (Leica DMI 4000B/DFC425C) was obtained from Leica (Wetzlar, Germany), a fluorescence qPCR instrument (ABI 7500, Applied Biosystems, Foster City, CA, USA) was obtained from Thermo Fisher Scientific (Waltham, MA, USA), and Image-Pro image analysis system was obtained from Bio-Rad (Hercules, CA, USA).

Modeling

The liver cancer model was established via injection of ascites containing Walker-256 liver cancer cell lines, specifically as follows: After anesthesia using 3% pentobarbital sodium solution (5 mL/kg) and disinfection, the abdominal cavity of rats was cut open to expose the liver in a supine position. Then the syringe was inserted obliquely into the liver tissues for about 0.5 cm to inject about 0.05 mL of cancerous ascites containing Walker-256 liver cancer cells (2×10^6 cells/ml). The bleeding point was pressed, and the abdominal cavity was closed and bandaged with sterile dressings.

Treatment in different groups

The rats underwent no treatment in normal group. In model group, the liver cancer model was established in the way described above, and an equal amount of normal saline was intraperitoneally injected every day after operation. In celecoxib group, the liver cancer model was also established in the way described above, and 0.2 mL of celecoxib solution (0.6 mg/ml) was injected every day after operation. At 30 d after modeling, the samples were taken.

Weighing and sampling

The body weight of rats was measured and recorded before modeling and before sampling, and the changes in the body weight of each rat were compared and analyzed. After weighing, the samples were taken as follows: After successful anesthesia, 6 rats in each group were fixed with paraformaldehyde, and liver cancer tissues were taken and fixed in 4% paraformaldehyde at 4°C for 48 h. Then the paraffin sections were prepared for HE staining and TUNEL assay. Besides, the samples were directly taken from the remaining 6 rats in each group: Liver cancer tissues were taken and placed into Eppendorf (EP) tubes for Western blotting, ELISA and qPCR. RIPA reagent (Beyotime) was utilized to extract protein from tissues and cells.

HE Staining

The tissues were fixed up, baked and prepared into paraffin sections. The sections were soaked in xylene solution and gradient alcohol and routinely deparaffinized and hydrated, respectively. Then the sections were stained using HE staining kits, and the staining was observed under a microscope. The sections were mounted when the staining was clear.

Western blotting

Liver tissues were lysed with RIPA (Beyotime), and then the supernatant was quantified using the bicinchoninic acid (BCA) method (Beyotime, Shanghai, China). After protein denaturation, the protein was then separated using sodium dodecyl sulphate-polyacrylamide
Celecoxib in rats with liver cancer

877

QPCR

gel electrophoresis (SDS-PAGE). Then the protein was transferred onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA), sealed with the TBST (25 mM Tris, 140 mM NaCl, and 0.1% Tween 20, pH 7.5) containing 5% skimmed milk for 1.5 h and incubated with the anti-p-ERK (1:1.000), anti-p-JNK (1:1.000) and anti-p-p38 primary antibodies (1:1.000) and secondary antibodies (1:1.000). After the membrane was washed with TBST, they were visualized using ECL reagents (Pierce, Rockford, IL, USA) and detected by ImageQuant LAS 4000 (Pittsburgh, PA, USA).

ELISA

Total RNA was extracted by using TRIzol reagent (Invitrogen, USA) and reversely transcribed into complementary DNA (cDNA) using the reverse transcription kit. The reaction system was 20 μL in total, and the reaction conditions were as follows: reaction at 51°C for 2 min, pre-denaturation at 96°C for 10 min, denaturation at 96°C for 10 s, annealing at 60°C for 30 s, a total of 40 cycles. The relative expressions of related messenger RNAs (mRNAs) were detected, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal reference. The primer sequences are shown in Table 1.

TUNEL assay

The sections were stained using TUNEL staining kits in the dark, mounted and observed under a fluorescence microscope.

Statistics

SPSS20.0 software (IBM, Armonk, NY, USA) was used for statistical analyses. Comparison between multiple groups was done using one-way ANOVA test followed by post hoc test (least significant difference). A p value<0.05 was considered statistically significant.

Results

Comparison of body weight

As shown in Figure 1, before modeling, there was no difference in the body weight of rats among groups (p>0.05). Before sampling, the body weight of rats was smaller in the model group and celecoxib group than that in the normal group (p<0.05), while it was larger in the celecoxib group than that in the model group (p<0.05).

HE staining results

The morphology of liver tissues was normal, hepatic lobules had intact and clear structure, and hepatocytes were arranged orderly without cell infiltration in the normal group. In the model group, the morphology of liver tissues was disordered, the structure of hepatic lobules was destroyed and disordered, and a large number of tumor cells could be seen (Figure 2). In the celecoxib group, the morphology of liver tissues was a little disordered but improved compared with that in the model group, the structure of hepatic lobules was destroyed, and some tumor cells could be seen.

Table 1. Primer sequences

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysteineyl aspartate specific proteinase 3 (Caspase3)</td>
<td>F: 5’-TCTTTTCCAGATGAACAAATGGC-3’</td>
</tr>
<tr>
<td></td>
<td>R: 5’-GCTGTTTTTTCGCTTGAAAATCTGC-3’</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>F: 5’-CTCCTCAGCTCTCGTTTCCTC-3’</td>
</tr>
<tr>
<td></td>
<td>R: 5’-CTCCTCAGCTCTCGTTTCCTC-3’</td>
</tr>
<tr>
<td>GAPDH</td>
<td>F: 5’-ACGGCAAGTTCACCGCAGACAG-3’</td>
</tr>
<tr>
<td></td>
<td>R: 5’-GAAGACGCCGAGTAGACTCCACGAC-3’</td>
</tr>
</tbody>
</table>

Figure 1. Comparison of body weight. Note: *p<0.05 vs. normal group, #p<0.05 vs. model group.
Related protein expressions detected via western blotting

Normal group had a lower protein expression of p-ERK and higher protein expressions of p-JNK and p-p38, while the protein expressions of p-ERK, p-JNK and p-p38 were the opposite in the model group (Figure 3A). The assessment of protein expression was conducted with Image J software. According to the statistical results (Figure 3B), the relative protein expression of p-ERK significantly rose, while that of p-JNK and p-p38 significantly declined in the other two groups compared with those in the normal group (p<0.05). Compared with those in the model group, the relative protein expression of p-ERK obviously declined, while that of p-JNK and p-p38 obviously rose in the celecoxib group (p<0.05).

Related mRNA expressions detected via qPCR

The relative mRNA expression of Caspase3 was markedly lower, while that of Cyclin D1 was markedly higher in the other two groups than those in the normal group (p<0.05). The relative mRNA expression of Caspase3 was markedly higher, while that of Cyclin D1 was markedly lower in the celecoxib group than those in the model group (p<0.05) (Figure 4).

ELISA results

The relative protein expression of Caspase3 greatly declined, while that of Cyclin D1 greatly rose in the other two groups compared with those in the normal group (p<0.05). The relative protein expression of Caspase3 greatly rose, while that of Cyclin D1 greatly declined in the celecoxib group compared with those in the model group (p<0.05) (Figure 5).

TUNEL assay results

The number of apoptotic cells (green color) was larger in normal group, but smaller in the other two groups (Figure 6A). As shown in Figure 6B, the apoptosis rate was remarkably decreased in the other two groups compared with that in the normal group (p<0.05), while it was remarkably increased in the celecoxib group compared with that in model group (p<0.05).
Discussion

Liver cancer is a common malignant tumor of the digestive system in China, and it mainly leads to severe emaciation, abdominal distension, ascites, dull pain in the liver, jaundice, hepatomegaly and even cachexia, ultimately causing death of patients [10,11]. Liver cancer has high morbidity and mortality rates, and its mortality rate is second only to lung cancer and gastric cancer, seriously threatening the life and health of Chinese people. Liver cancer is characterized by insidious onset and rapid development, so the patients have often been in late stage when diagnosed. Studies have shown that hepatitis, including viral hepatitis and alcoholic hepatitis, is an important pathogenic factor of liver cancer. It is currently believed that the pathogenesis of liver cancer is complex and involves a variety of physio-pathological reactions and pathological mechanisms, including gene mutations, abnormalities of signal transduction pathways, cell proliferation and apoptosis [10-13]. At present, surgical resection, chemoradiotherapy, interventional therapy and immunotherapy are dominating in the treatment of liver cancer, but there have been no ideal treatment methods yet. Therefore, it is of great importance to deeply study the related pathological mechanism of liver cancer and explore the related treatment methods based on this.

During the pathogenic process of liver cancer, excessive proliferation and low apoptosis level of liver cancer cells are the key factors to the occurrence and rapid development of liver cancer, and they are also the starting points for the effective inhibition on the development of liver cancer and its treatment. Studies have demonstrated that liver cancer cells have strong proliferation ability but apoptosis rarely occurs, which may be one of the important reasons for the rapid development of this disease [14-16]. Therefore, intervention based on these characteristics of liver cancer cells is a new idea for the treatment of liver cancer. The ERK/JNK/p38 signaling pathway plays an important regulatory role in the proliferation and apoptosis of liver cancer cells. It has been found that the phosphorylation levels of key molecules in the ERK/JNK/p38 signaling pathway (ERK, JNK and p38) have great changes in liver cancer tissues [17-19]. A large number of ERKs are phosphorylated to significantly increase their phosphorylation level, and then the massive expression of Cyclin D1 closely related to cell proliferation is promoted, thereby facilitating the proliferation of a large number of liver cancer cells. Meanwhile, the phosphorylation levels of JNK and p38 greatly decline, so that the expression of Caspase3 closely related to apoptosis is obviously decreased, thus making the apoptosis of liver cancer cells at a low level. In this study,
the results further confirmed that the ERK/JNK/p38 signaling pathway had significant changes in liver cancer tissues, in which p-ERK had a markedly increased expression and p-JNK and p-p38 had markedly decreased expressions, consistent with the results of previous studies.

Celecoxib, one of the non-steroidal anti-inflammatory drugs, possesses a good antipyretic and analgesic effect, and it has been widely applied in the clinical treatment of muscle pain, inflammation, etc. A study has shown that celecoxib can better inhibit growth and promote apoptosis of tumor cells, thereby exerting a significant anti-tumor effect [20]. In this study, the findings confirmed that celecoxib could markedly inhibit the proliferation and promote the apoptosis of liver cancer cells, and improve the body weight of rats with liver cancer, thereby exerting a good anti-tumor effect. To study its related mechanism, the expressions of key molecules in the ERK/JNK/p38 signaling pathway closely related to the proliferation and apoptosis of liver cancer cells were determined. The results showed that celecoxib could remarkably suppress the expression of p-ERK and promote the expressions of p-JNK and p-p38, thus enhancing the massive apoptosis of liver cancer cells. In conclusion, celecoxib affects the apoptosis of liver cancer cells through regulating the ERK/JNK/p38 signaling pathway, thereby exerting an anti-tumor effect.

Conclusions

In conclusion, celecoxib affects the apoptosis of liver cancer cells through regulating the ERK/JNK/p38 signaling pathway, thereby exerting an anti-tumor effect.

Conflict of interests

The authors declare no conflict of interests.

References

17. Xu C, Shen G, Yuan X et al. ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates

